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Abstract
 
Rac2 is a hematopoietic-specific GTPase acting as a molecular switch to mediate both transcrip-
tional activation and cell morphological changes. We have examined the effect of Rac2 defi-
ciency during T cell activation. In Rac2
 
 
 
/
 
 
 
 T cells, proliferation was reduced upon stimulation
with either plate-bound anti-CD3 or T cell receptor–specific antigen. This defect is accompanied
with decreased activation of mitogen activated protein kinase extracellular signal–regulated kinase
(ERK)1/2 and p38, and reduced Ca
 
2
 
 
 
 mobilization. TCR stimulation–induced actin polymer-
ization is also reduced. In addition, anti-CD3 cross-linking–induced T cell capping is reduced
compared with wild-type T cells. These results indicate that Rac2 is important in mediating both
transcriptional and cytoskeletal changes during T cell activation. The phenotypic similarity of
Rac2
 
 
 
/
 
 
 
 to Vav
 
 
 
/
 
 
 
 cells implicates Rac2 as a downstream mediator of Vav signaling.
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Introduction
 
After the engagement of TCR and its specific ligand, pep-
tide/MHC complexes, a cascade of biochemical changes
occur leading to transcriptional activation and cell cytoskel-
etal reorganization. Engagement of TCRs cause the activa-
tion of Src and Syk/ZAP-70 family proteins and the tyro-
sine phosphorylation of various cellular substrates, calcium
(Ca
 
2
 
 
 
) mobilization, and activation of mitogen-activated
protein kinases (MAPKs)
 
*
 
 including extracellular signal–
regulated kinase (ERK), c-Jun NH
 
2
 
-terminal kinase (JNK),
and p38, thus translating the receptor signal to transcrip-
tional activation of effector genes. Simultaneously, TCR
engagement also causes cytoskeleton reorganization, results
in T cell polarization toward APCS, enhanced T cell
APC interaction, and supramolecular activation clusters
(SMACs) formation (1). These biochemical and cytoskele-
tal changes are well orchestrated and ensure sustained TCR
signaling, leading to T cell proliferation, differentiation,
and cytokine production. Compromising either biochemi-
cal or cytoskeletal changes results in dampened T cell re-
sponse to stimulation (2). Thus, molecules orchestrating
these two aspects play a key role in T cell activation.
Rac proteins are members of the Rho GTPase family
and cycle between the active GTP-bound form and the
inactive GDP bound form. Activated Rac binds to a vari-
ety of down stream effector molecules thereby mediating
multiple cellular functions in different cell types (3). Spe-
cifically, Rac is well known for its involvement in cyto-
skeleton reorganization. Activation of Rac is associated
with changes in actin polymerization, causing lamellipo-
dia formation and membrane ruffles in fibroblasts (4, 5),
morphological changes in platelets (6), and facilitating cell
adhesion and chemotaxis response in macrophages and
neutrophils (7–9). Rac also participates in signal transduc-
tion via mitogen-activated kinase pathways. In vitro stud-
ies indicate that by activating PAK1, a well known Rac
target, Rac can activate ERK in T cells upon TCR stim-
ulation (10), and in NK cells upon interaction with the
target cell (11). Rac also activates c-Jun NH
 
2
 
-terminal ki-
nase and p38 kinase pathways through PAK1 (12, 13).
Moreover, Rac GTPases play an important role in cell
cycle progression and survival in response to mitogenic
stimulation (14, 15), and are essential for cellular transfor-
mation by Ras (16, 17). Furthermore, Rac is essential for
the activation of a multiprotein complex that produces
superoxide in phagocytic cells, the NADPH oxidase (9,
18–20).
While the function and biochemical properties have been
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Rac2 and T Cell Activation
 
well studied in many cell types, the role of Rac GTPases
during T cell activation is less clear. Studies from Vav-defi-
cient mice suggest that Rac could play an important role in
T cell activation (21–23). Vav is a guanine nucleotide ex-
change factor (GEF), enhancing the exchange of GDP to
GTP, thus promoting the activation of Rho GTPase. In
vitro, Rac GTPase has been shown to be a major substrate
of Vav GEF activity (24). Upon T cell stimulation, Vav is
rapidly activated through phosphorylation. In the absence
of Vav, T cells exhibit a profound activation defect, with
decreased proliferation in response to anti-CD3 in the pres-
ence and absence of anti-CD28, and decreased IL-2 pro-
duction (21–23). Biochemical analysis of Vav
 
 
 
/
 
 
 
 T cells
showed that although early tyrosine phosphorylation of
Zap70, Cbl-c, SH2 domain–containing leukocyte protein
of 76 kD (SLP-76), and linker for activation of T cells
(LAT) are normal, ERK and nuclear factor (NF)-
 
 
 
B acti-
vation are defective upon TCR stimulation. TCR induced
Ca
 
2
 
 
 
 flux is also defective. Moreover, Vav
 
 
 
/
 
 
 
 T cells
showed defects in actin polymerization and cap formation
in response to TCR stimulation (21–23). As the Rac GTP-
ase is a major substrate for Vav GEF activity and has
demonstrated its function in both transcriptional activa-
tion and cytoskeleton reorganization, it is conceivable that
at least part of the phenotype of Vav knockouts may de-
rive from the defective activation of Rac. Most recently,
using an in vitro system, Arrieumerlou et al. have demon-
strated that dominant negative Rac affects Ca
 
2
 
 
 
 mobiliza-
tion and actin polymerization in response to TCR cross-
linking (25). These results indicate that Rac could play an
important role in T cell activation. However, as dominant
negative small GTPases are pleiotropic in action, it is pos-
sible that this effect is mediated through other proteins
such as Ras or Rho. Moreover, there are three members
within the Rac subfamily, Rac1, Rac2, and Rac3. While
Rac1 is universally expressed, the expression of Rac2 is
restricted to the hematopoietic lineage (26). Rac3 is a rel-
ative newly described member of Rac family and is highly
expressed in brain (27). As Rac proteins are highly ho-
mologous to each other, sharing 89–92% sequence ho-
mology, it is plausible that there are functional overlaps
between Rac proteins.
In this report, we studied the role of the hematopoietic-
specific GTPase Rac2 in T cell activation using Rac2-defi-
cient mice (9). T cell activation was compromised in
response to either anti-CD3 or TCR-specific antigen. Co-
stimulation with anti-CD28 or adding IL-2 partially
compensates for the proliferation defect. Biochemically,
Rac2
 
 
 
/
 
 
 
 T cells showed decreased phosphorylation of
ERK1/2 and p38. Antigen-induced Ca
 
2
 
 
 
 flux is also re-
duced. Moreover, actin polymerization upon TCR cross-
linking or antigen stimulation is decreased. This defective
cytoskeletal change is accompanied by decreased cap for-
mation. These results indicated that deficiency of Rac2 af-
fects both transcriptional activation and cytoskeleton reor-
ganization during T cell stimulation, and suggests that
defective Rac activation is partially responsible for the ob-
served defects in Vav
 
 
 
/
 
 
 
 mice.
 
Materials and Methods
 
Mice.
 
B10. BR mice were obtained from The Jackson Labo-
ratory. AND TCR transgenic mice with CD4
 
 
 
 T cells express-
ing a TCR specific for the COOH terminus of pigeon cyto-
chrome c have been described (28) and were maintained on the
C57BL/6 background in our facility. Rac2 knockout mice
(Rac2KO) on the C57BL/6 background have been described (9).
Rac2KO mice were further bred with AND TCR transgenic
mice. All mice were maintained in pathogen-free condition and
were used at 6–12 wk of age.
 
Preparation of APC, CD4
 
 
 
, CD8
 
 
 
 Mature T Cells and Thy-
mocytes Subpopulations.
 
T cell–depleted APC were prepared by
incubating B10BR splenocytes with anti–Thy-1, anti-CD8, anti-
CD4, and anti-NK1.1 antibody, followed by complement medi-
ated lysis. CD4
 
 
 
 T cells from spleens and lymph nodes were iso-
lated by immunomagnetic negative selection using antibodies
against CD8, NK1.1, and MHC class II, followed by incubation
with anti–mouse and anti–rat Ig-coated magnetic beads (PerSep-
tive Biosystems). Mature CD8
 
 
 
 T cells were isolated in the simi-
lar manner as CD4
 
 
 
 T cells. CD4
 
 
 
CD8
 
 
 
 and CD4
 
 
 
 thymocytes
were isolated by flow cytometry sorting. CD4
 
 
 
CD8
 
 
 
 and CD8
 
 
 
thymocytes were isolated by depleting CD4
 
 
 
 cells in total thy-
mocytes first, followed by separation of CD8
 
 
 
 and CD4
 
 
 
CD8
 
 
 
cells using MACs column according to the manufacturer’s sug-
gestion (Miltenyi Biotec).
 
T Cell Proliferation and IL-2 Production.
 
10
 
5
 
 purified CD4
 
 
 
 T
cells were cultured in triplicate in round-bottom plate precoated
with anti-CD3 antibody (clone 145–2C11) with or without anti-
CD28. Alternatively, 10
 
5
 
 AND TCR transgenic CD4
 
 
 
 cells
were cocultured with 10
 
5
 
 mitomycin C treated I-E
 
k
 
 
 
 CH27 cells
or B10BR APCs in the presence of different doses of MCC pep-
tide (VFAGLKKANERADLIAYLKQATK). T cells were pulsed
with 1 
 
 
 
Ci/well [
 
3
 
H]thymidine 48 h after stimulation and were
harvested 12 h later. The level of [
 
3
 
H]thymidine incorporation
was determined by scintillation counting. IL-2 production was
measured by ELISA (BD PharMingen) 24 h after stimulation.
 
Immunoblotting.
 
AND TCR transgenic T cells were stimu-
lated with either fresh or paraformaldehyde fixed B10BR APCs
prepulsed with MCC peptide. At the indicated time point, cells
were harvested and lysed in ice-cold lysis buffer (20 mM Tris, pH
7.2, 1% NP-40, 150 mM NaCl, 1 mM MaCl
 
2
 
, 1 mM EDTA)
containing protease and phosphatase inhibitors. Nuclear material
was removed by centrifuging at 13,000 rpm for 15 min. Superna-
tant of the cell lysate was electrophoresed on a 12.5% SDS-PAGE
gel, transferred to immunoblot membrane, and blotted with the
indicated antibody. Antibody against phospho-tyrosine 4G10 was
obtained from Upstate Biotechnology. Antibodies against phos-
pho-ERK, ERK, phospho-p38, p38, Phospho-JNK, and JNK
were obtained from New England Biolabs, Inc. and were used as
directed. To check for rac protein expression in different popula-
tion of mature T cell and thymocytes, 50 
 
 
 
g of cell lysates from
each cell population were used for Western blotting. Rac1 anti-
body was from Santa Cruz Biotechnology, Inc., and Rac2 anti-
body was provided by Gary M. Bokoch from the Scripps Re-
search Institute, La Jolla, CA.
ERK kinase assay AND TCR transgenic T cells were stimu-
lated with fresh B10BR APCs prepulsed with MCC peptide for
the indicated time. Cells were then lysed in the aforementioned
lysis buffer. ERK kinase activity were assayed using MAPK Im-
munoprecipitation Kinase Assay Kit (Upstate Biotechnology) fol-
lowing the manufacturer’s protocol.
 
Ca
 
2
 
 
 
 Mobilization.
 
Calcium signaling after Ag-specific stimu-
lation was monitored as described previously (29). Briefly, CD4
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T cells loaded with 5 
 
 
 
M fluo3/AM ester (Molecular Probes)
were plated by centrifugation in flat 96-well plates at a concentra-
tion of 5 
 
 
 
 10
 
5
 
 cell/50 
 
 
 
l. The cells were then scanned using the
ACAS 570 video laser cytometer (Meridian Instruments). After
initiation of scanning, 4 
 
 
 
 10
 
6
 
 T cell–depleted splenocytes pulsed
with peptide was added to the CD4
 
 
 
 T cells. To examine anti-
body cross-linking–induced Ca
 
2
 
 
 
 flux, fluo3/AM loaded T cells
were incubated with the indicated amount of anti-CD3 antibody
for 5 min, then recovered by centrifugation in a microcentrifuge
(2,000 rpm for 3 min), resuspended, and plated in a flat 96-well
plate. The cells were then scanned for 1 min followed by addi-
tion of cross-linking antibody anti–hamster IgG (100 
 
 
 
g/ml).
The initial average fluorescence of each cell was digitized and
normalized to 1, and the results are expressed as changes in nor-
malized fluorescence intensity of individual cells over time. The
percentage of responding cells was determined by dividing the
number of cells demonstrating an increase in intracellular calcium
of 
 
 
 
50% by the total number of scanned cells
 
.
 
 The time from the
addition of the antibody to the start of Ca
 
2
 
 
 
 flux was recorded
among 100 Rac2
 
 
 
/
 
 
 
 and Rac2
 
 
 
/
 
 
 
 cells studied.
 
Actin Polymerization.
 
To measure changes in actin polymeriza-
tion upon TCR cross-linking, CD4
 
 
 
 T cells were incubated with
anti-CD3 antibody (1 
 
 
 
g/ml) on ice for 30 min, followed by wash-
ing and cross-linking with anti–hamster IgG (3 
 
 
 
g/ml) for the in-
dicated time. Alternatively, AND TCR transgenic T cells were
mixed with equal number of CH27 APCs preloaded with various
amounts of MCC peptide. T cell APC interaction was initiated by a
quick spin of the cell mixture followed by incubation at 37
 
 
 
C for
the indicated time. Activation was terminated by addition of 4%
paraformaldehyde. After fixation, cells were incubated with FITC-
conjugated phalloidin (Sigma-Aldrich) for 30 min, washed three
times in PBS, and analyzed using a FACSCalibur™ flow cytometer.
 
Capping and Immunofluorescence Study.
 
10
 
6
 
 CD4
 
 
 
 T cells were
incubated with anti-CD3 at the indicated concentrations on ice for
30 min. After washing, cells were further incubated with biotiny-
lated anti–hamster Ig (3 
 
 
 
g/ml) at 37
 
 
 
C for 30 min, followed by
addition of 4% paraformaldehyde to fix cells. Fixed cells were
stained with Avidin-Texas Red (BD PharMingen) and were
cytospun onto slides and mounted with Vectorshield (Vector Lab-
oratories). The cells were visualized with a ZEISS fluorescence mi-
croscope. The percentage of capped cells was obtained by count-
ing cells from 10–15 random fields and a total of more than 100
cells were counted per experimental condition in each experiment.
 
Results
 
Rac2 Deficiency Affect T Cell Activation.
 
Rac2 is a GTP-
ase specifically expressed in hematopoietic lineage cells. To
study the role of Rac2 during T cell activation using
Figure 1. Rac protein expression and T cell develop-
ment in Rac2 /  and Rac2 /  mice. (A) Rac1 and Rac2
protein expression in subpopulation of thymocytes and
mature peripheral T cells. 50  g of cleared cell lysate from
each cell population was used for Western blotting. The
same blot probed for Rac1 was stripped and reprobed for
Rac2. Lane 1 and 7, mature CD4  cells; lane 2 and 8, ma-
ture CD8 cells; lane 3 and 9, CD4 CD8  thymocytes;
lane 4 and 10, CD4 CD8  thymocytes; lane 5 and 11,
CD4  thymocytes; lane 6 and 12, CD8  thymocytes. The
rac2 antibody weakly cross reacts with another protein in
lysates from Rac2 /  cells and the control cells (reference
9). Data represents one of two experiments. (B) Lymph
node cells or thymocytes were isolated from Rac2 /  mice
and its littermate Rac2 /  mice. The expression of CD4
and CD8 was examined by two-color flow cytometry. 
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Rac2 and T Cell Activation
 
Rac2KO mice, we first examined the expression pattern of
Rac proteins among subpopulation of thymocytes and ma-
ture peripheral T cells in wild-type and Rac2KO mice. As
shown in Fig. 1 A, while Rac1 showed lower level of ex-
pression in CD4
 
 
 
 cells, Rac2 showed higher expression in
CD4
 
 
 
 thymocytes and mature CD4 and CD8 single-posi-
tive cells. Upon disruption of Rac2, there is compensatory
overexpression of Rac1 in CD4
 
 
 
 thymocytes and mature
T cells (Fig. 1 A). Analysis of peripheral T cell subsets dem-
onstrated no significant alterations in cell number or distri-
bution. Thymocyte cellularity and subsets were also similar
to wild-type mice (9). Thus, T cell development was not
grossly altered in Rac2
 
 
 
/
 
 
 
 mice (Fig. 1 B). This normal T
cell development may partly due to the compensatory ef-
fect of Rac1 in the Rac2KO mice. To study the functional
consequences of the Rac2 deficiency in T cell activation,
we first examined the proliferation of total splenocytes
stimulated with a dose range of plate bound anti-CD3. As
shown in Fig. 2 A, decreased proliferation was observed in
Rac2
 
 
 
/
 
 
 
 total splenocytes. Purified CD4
 
 
 
 T cells were fur-
ther studied by stimulating with a dose range of plate-
bound anti-CD3. Rac2
 
 
 
/
 
 
 
 CD4 T cell proliferation was
reduced about twofold upon stimulation with plate-bound
anti-CD3 (Fig. 2 B). The addition of IL-2 partially com-
pensated for the defect in T cell activation, suggesting that
IL-2 production is compromised in the Rac2
 
 
 
/
 
 
 
 T cells
and is partially responsible for the proliferation defect (Fig.
2 C). Costimulation with anti-CD28 also compensated for
the T cell proliferation defect (Fig. 2 C). As anti-CD28
stimulation alone can cause Vav phosphorylation (30, 31),
it is plausible that costimulation of anti-CD28 further acti-
vates other Rho GTPases such as Rac1 and Rac3, thus
compensating for the Rac2 deficiency. Interestingly, Rac2-
deficient B cells also showed reduced proliferation upon
stimulation with anti-IgM plus IL-4 (
 
P 
 
  
 
0.01; Fig. 2 D).
To study Rac2 function during T cell activation in a
more physiologically relevant context, Rac2
 
 
 
/
 
 
 
 mice was
crossed with AND TCR transgenic mice on the C57B/6
background. The AND TCR transgenic mouse expresses
V
 
 
 
11/V 3 TCR recognizing a peptide of cytochrome c
(pigeon cytochrome c fragment) presented on IEk-bearing
APCs (28). Although the AND TCR can be positively se-
lected on I-Ab in the thymus, it cannot recognize MCC
peptide on H-2b APC (32), therefore effectively eliminat-
ing any contribution of APC contaminants in the T cell
preparation. The expression of TCR transgene was assessed
by flow cytometry using V 11 and V 3 antibody. A simi-
lar percentage of V 11/V 3 CD4  cells in the lymph
node and spleen was observed in Rac2 /  TCR transgenic
compared with the wild-type mice (data not shown), indi-
cating that Rac2 deficiency does not significantly affect T
cell–positive selection in the thymus. Rac2 /  CD4 
TCR transgenic cells were stimulated with I-EK  splenic
APCs with varying amount of MCC peptide. Proliferation
was two- to threefold lower in Rac2 /  T cells compared
with the control (Fig. 3 A). I-EK  CH27 cells, which con-
stitutively express both CD80 and CD86 molecules, were
also used to stimulate TCR transgenic CD4 cells. Although
the proliferation was much more vigorous compared with
the stimulation with resting splenic APCs, Rac2 /  T cells
still showed a two- to threefold lower level of proliferation
(Fig. 3 B), accompanied by a lower level of IL-2 produc-
tion (Fig. 3 C). Similar defects were also observed when
stimulating T cells with fibroblast APCs (DCEK-Hi7; ref-
erence 33) expressing I-Ek and B7 molecules (data not
shown). This result suggests that the activation defect in
Figure 2. Defective T cell
proliferation upon stimulation of
plate-bound anti-CD3. (A) Sple-
nocytes from Rac2 /  and con-
trol mice were stimulated with
varying amounts of plate-bound
anti-CD3. WT, wild-type. (B)
Purified CD4 T cells stimulated
with a dose range of plate-bound
anti-CD3. (C) Purified T cells
were stimulated with plate-
bound anti-CD3 (5  g/ml)
alone, in the presence of IL-2
(50  /ml), or plate-bound anti-
CD28 (2.5  g/ml). (D) Purified
B cells were stimulated with
anti-IgM (10 g/ml), anti-IgM
(10  g/ml)   IL-4 (1,000 U/ml),
or LPS (1  g/ml). [3H]Thymi-
dine was pulsed 48 h after stimu-
lation and harvested 12 h later.
Data represent one of three sepa-
rate experiments.919 Yu et al.
Rac2 /  T cells cannot be overcome using activated
APCs. It is also consistent with previous findings that plate-
bound anti-CD28 stimulation is different from stimulation
with nature B7 ligand (30).
Decreased ERK, p38 Activation upon T Cell Stimulation.
To understand the mechanism that accounts for the T cell
functional defect in Rac2 /  mice, we first studied the
early biochemical changes upon T cell stimulation. Total
tyrosine phosphorylation was examined in CD4  T cells
after stimulation with antigen pulsed APCs for the indi-
cated time. There was no significant change in the total ty-
rosine phosphorylation pattern in Rac2 /  T cells com-
pared with the wild-type controls (Fig. 4 A). Further
examination of the phosphorylation pattern of Zap70 and
PLC- 1 by immunoprecipitation showed no significant
difference between Rac2 /  and control T cells (data not
shown). TCR stimulation has been reported to cause acti-
vation of the MAPK pathway (34–37). As a signaling mol-
Figure 3. Defective T cell proliferation and IL-2 production upon stimulation with TCR-
specific antigen. Purified CD4  T cells from AND TCR transgenic Rac2 /  or control mice
were stimulated with various doses of MCC peptide in the presence of B10BR splenic APCs
(A) or I-EK   CH27 cells (B and C). [3H]Thymidine was pulsed 48 h after stimulation and har-
vested 12 h later (A and B). To measure IL-2 production, supernatant were harvested 24 h after
stimulation and the amount of IL-2 were determined by ELISA (C). Data represent one of four
(A) or one of two (B and C) separate experiments.
Figure 4. Reduced MAPK
activation upon TCR stimula-
tion. Purified CD4  T cells (2  
106) from AND TCR transgenic
Rac2 /  or control mice were
stimulated with B10BR splenic
APCs (2   106) pulsed with 50
 g/ml MCC peptide for 1, 5,
and 15 min at 37 C. Cell lysates
were separated by 12.5% SDS-
PAGE and subject to immuno-
blot analysis. (A) Analysis of total
phosphotyrosine proteins after
stimulation using anti-phospho-
tyrosine antibody. (B) Analysis of
phosphorylation of ERK1/2
using phospho-ERK antibody.
The same blot was stripped and
reprobed with ERK kinase anti-
body to confirm equal protein
loading. (C) Analysis of ERK
kinase activity. (D) Analysis of
phospho-p38. Protein loading
was confirmed by reprobing
with antibody against total p38
(data represent one of four sepa-
rate experiments except ERK ki-
nase analysis represent one of
two separate assays).920 Rac2 and T Cell Activation
ecule, Rac has been shown to contribute to the activation
of the Ras pathway through PAK (10, 11). In addition,
overexpression of Rac has been demonstrated to activate
the JNK and p38 pathways (12). Thus, we further exam-
ined the activation of ERK, JNK, and p38 in Rac2 /  T
cells during antigen-specific stimulation. As shown in Fig.
4 B, although Rac2 /  T cells showed increased ERK1/2
phosphorylation upon stimulation, the level of ERK1/2
activation is reduced compared with the control. We fur-
ther examined ERK kinase activity upon stimulation. Con-
sistent with what was observed in ERK1/2 phosphoryla-
tion, decreased ERK activity was observed 1 min after
stimulation (Fig. 4 C). A slight decrease in p38 phosphory-
lation was also observed in Rac2 /  T cells (Fig. 4 D). Lit-
tle phosphorylated JNK was detected upon stimulation in
both wild-type and Rac2 /  T cells (data not shown). This
is consistent with previous studies from our laboratory
which showed that JNK protein is only expressed at low
levels in naive T cells, and is upregulated during T cell acti-
vation and therefore functions during the differentiation
rather than activation of T cells (38, 39).
Reduced Ca2  Mobilization upon TCR Stimulation. Ca2 
mobilization is an early event during T cell activation and is
responsible for the activation of Ca2  sensitive phosphatase
Calcineurin and nuclear factor of activated T cells (NFAT)
mobilization (40). We further examined Ca2  mobilization
during antigen-specific stimulation. As shown in  A, upon
addition of antigen-pulsed APCs, the number of Rac2 / 
CD4  T cells to undergo Ca2  flux was decreased com-
pared with the CD4 T cells from wild-type mice at both
high and low antigen doses tested (Fig. 5 A). To rule out
that the decreased number of Ca2  responsive cells was due
to decreased T cell–APC interaction rather than defective
Ca2  mobilization, we also examined Ca2  flux in response
to TCR cross-linking. At a low dose of anti-CD3, there is
lower Ca2  flux among the responding cells in Rac2 /  T
cells compared with the wild-type control (Fig. 5 B). In
addition, Rac2 /  cells exhibited a longer lag time to Ca2 
increase compared with Rac2 /  cells, which were more
synchronized in their response. The average responding
time was 217   72 s for Rac2 /  T cells versus 155   60 s
for wild-type stimulated with 0.1  g/ml anti-CD3 (P  
0.01). At higher doses of anti-CD3, Rac2 /  T cells
showed similar pattern of Ca2  mobilization as wild-type T
cells (Fig. 5 B, and data not shown).
Defective Cytoskeleton Changes. TCR activation leads to
cytoskeletal reorganization in T cells. As Rac proteins have
been shown to mediate actin polymerization and cell shape
changes (3–5), we further investigated whether deficiency
of Rac2 affects TCR-induced actin polymerization. Puri-
fied CD4  cells were cross-linked with anti-CD3 antibody
and actin polymerization was analyzed quantitatively using
phalloidin labeled with FITC. Phalloidin preferentially
binds to polymerized filamentous actin (F-actin). Although
a significant increase in actin polymerization was observed
in Rac2 /  T cells, the level of polymerization was at a re-
duced level in comparison to the wild-type control (Fig. 6
A). Similar results were obtained when TCR transgenic T
cells were stimulated with APC pulsed with various
amount of antigen (Fig. 6 B, and data not shown). These
results indicate that Rac2 plays a role in mediating TCR-
induced cytoskeleton changes.
Defective Cap Formation and T Cell APC Interaction. We
further investigated an actin dependent event upon TCR
stimulation: TCR capping. Upon antibody cross-linking,
TCR molecules cluster into a cap structure (1). Capping
has been demonstrated to require actin polymerization and
is blocked by Cytochalasin D (22, 41). To investigate
whether antibody cross-linking–induced TCR capping is
affected in Rac2 /  cells, purified T cells were incubated
with a range of concentrations of anti-CD3 at 4 C, and was
subsequently cross-linked with anti–hamster IgG and incu-
bated at 37 C for 30 min. At all doses of anti-CD3 anti-
body, a reduced number of cells with capped TCR was
observed in Rac2 /  T cells (Fig. 7).
Discussion
Rac GTPase plays important roles in both transcriptional
activation and cytoskeletal reorganization in a variety of
cell types. In this study, we examined the function of he-
matopoietic-specific Rac2 GTPase during T cell activation.
In the absence of Rac2, T cell activation stimulated by ei-
ther antibody or TCR-specific antigen was defective. This
defective T cell activation was accompanied by aberrant
biochemical changes manifested as decreased ERK, p38 ac-
tivation, Ca2  mobilization, and defective actin polymer-
ization which affects TCR capping. Consistent with these
in vitro observations, reduced delayed-type hypersensitivity
response was observed (data not shown).
Upon T cell stimulation, the small GTPase Ras is rapidly
activated and leads to Raf activation, which in turn acti-
vates MEK1, and ERK. ERK activation is involved in me-
diating cellular proliferation, transformation, and differenti-
ation. Although Rac GTPase is well known for its ability
to activate the JNK and p38 pathways, activated Rac alone
has little effect in activating the ERK pathway (12, 42).
However, accumulating evidence suggests that Rac can
also influence ERK activation through its target PAK (10,
11, 43). In 293 cells, overexpression of either a dominant
negative Rac2 or PAK inhibits Ras-mediated activation of
ERK2, whereas constitutively active Rac synergizes with
active Raf to increase ERK2 activity (43). In T cells, dom-
inant negative PAK also inhibits TCR-mediated ERK2 ac-
tivation (10). Activated PAK may influence ERK activa-
tion through phosphorylation of MEK1 and/or Raf1 (44).
Similar to the findings in Vav /  T cells and Rac2 /  neu-
trophils (9, 23), we have observed decreased ERK1/2
phosphorylation upon TCR stimulation. As in many other
studies on early T cell activation (45–47), biochemical
changes were observed in T cells stimulated with live anti-
gen-pulsed APCs. To rule out the possibility that decreased
ERK phosphorylation reflects changes in APCs rather than
in T cells, we used fixed APCs prepulsed with antigen and
obtained the same result (data not shown). Furthermore,
reduced ERK activation was also observed in Rac2 /  T921 Yu et al.
Figure 5. Reduced calcium mobilization in Rac2 /  T
cells. (A) AND TCR transgenic CD4 cells were loaded
with the Ca2  sensitive fluorochrome, fluo-3, and stimu-
lated with splenic APCs prepulsed with 50  g/ml or 0.5
 g/ml MCC peptide. (B) CD4 T cells loaded with fluo-3
were stimulated with 0.1 or 1  g /ml anti-CD3. The per-
centage of responding cells and the pattern of response in
individual T cells was examined using a video laser cytom-
eter. Each graph indicates the pattern of Ca2  mobilization
in a field of 40 to 50 cells, in which each line represents the
average fluorescent intensity of an individual T cell over
time. The first arrow indicates the addition of APC pulsed
with peptide or cross-linking antibody, and the second ar-
row indicates the addition of ionomycin (666 ng/ml). S
stands for sustained response, i.e., increased calcium con-
centration lasting  5 min. T stands for transient response,
i.e., calcium increase lasting less than 5 min.922 Rac2 and T Cell Activation
cells stimulated in the absence of APCs, by anti-CD3 cross-
linking (data not shown). This result is consistent with the
aforementioned in vitro findings that Rac influences the
activation of the ERK pathway. In reference to results
from Vav /  T cells showing decreased ERK activation
(23), our result is also consistent with the hypothesis that
TCR-stimulated tyrosine phosphorylation of Vav pro-
motes its GEF activity toward Rac, which in turn activates
PAK and ERK (10). As the activation of the ERK pathway
plays an important role in TCR-mediated AP-1 induction
and cell cycle progression, defective ERK activation may
be partially accountable for the observed proliferation de-
fect in Rac2 /  T cells.
MAPK p38 is activated by cellular stresses, inflammatory
cytokines, LPS, and G protein–coupled receptors (48–51).
During T cell activation, p38 is activated with either anti-
CD3 or anti-CD28 in primary lymphocytes and its activa-
tion correlates closely with T cell proliferation (37). How-
ever, how p38 influence primary T cell activation is less
clear. As T cell proliferation is normal in response to anti-
CD3 or ConA in dominant-negative p38 transgenic mice,
activated p38 may mainly affect T helper 1 cell differentia-
tion rather than directly affect T cell activation (52). Con-
sistent with these studies, we observed decreased p38 acti-
vation in Rac2 /  T cells, accompanied with decreased T
cell proliferation and T helper 1 cell differentiation (53).
Calcium mobilization is a crucial event during T cell ac-
tivation. This process is achieved through the activation of
phospholipase C-  (PLC- ) to catalyze the hydrolysis of
phosphatidylinositol 4,5 bisphosphate (PIP2) to diacylglyc-
erol and inositol 1,4,5-triphosphate (IP3), which activate
protein kinase C and elevates intracellular calcium, respec-
tively. In this study, we have observed decreased Ca2  flux
upon TCR stimulation by antigen or antibody cross-link-
ing. Several potential mechanisms may explain this Ca2 
mobilization defect. First, Rac may affect Ca2  mobiliza-
tion by modulating the level of PIP2, the substrate for
PLC- . Previously, Rho and Rac have been implicated in
the activation of phosphatidylinositol 4-phosphate 5-kinase
(PIP5K), which in turn phosphorylates phosphatidylinosi-
tol 4 phosphate (PIP), resulting in the production of PIP2
(6, 54). Decreased activation of PIP5K may leads to re-
duced level of PIP2, decreased production of IP3, hence
decreased Ca2  mobilization. Alternatively, Rac may affect
the activation of PLC-  through phosphatidylinositol 3-kinase
(PI3K) activation. Recent studies suggests that phosphati-
dylinositol 3,4,5-trisphosphate (PIP3), a catalytic product
of PI3K, can activate and synergize with phosphorylated
PLC-  to achieve full-scale Ca2  mobilization (55, 56). As
PI3K may act downstream of Rac (57), Rac may affect
Ca2  flux through PI3K activation. Lastly, inhibition of ac-
tin polymerization in thymocytes and human T cell lines
also reduces Ca2  flux during activation mediated by spe-
Figure 6. Impaired actin polymerization upon T cell stimulation. CD4 
T cells were stimulated by anti-CD3 cross-linking (A) or with CH27 cells
(B) prepulsed with 0.5  g /ml of MCC peptide. Cells were fixed after
stimulation for the indicated time and polymerized actin was measured by
phalloidin staining. Data showing one of three representative experiments.
Figure 7. Reduced cap formation in Rac2 /  T cells. Purified CD4 T
cells coated with a dose range of anti-CD3 were cross-linked with biotin-
ylated anti–hamster antibody and further incubated at 37 C for 30 min
followed by fixation. TCR cap formation was visualized by staining with
Texas-red-Avidin and analyzed by immunofluorescence microscopy. (A)
Representative T cell capping in Rac2 /  and control cells. (B) Percent-
age of capping at different dose of anti-CD3. Data represents at least three
separate experiments.923 Yu et al.
cific peptide/MHC complex on APCs (58, 59). We have
observed decreased actin-polymerization in Rac2 /  T
cells upon stimulation, which may account for the de-
creased Ca2  mobilization.
T cell activation is accompanied by rapid cytoskeletal
changes and formation of a cap upon antibody cross-link-
ing, or SMACs at the interfaces of physical contact be-
tween T cells and APCs (1, 60). It has been proposed that
receptor clustering could favor sustained T cell signaling in
three ways: first, by increasing the likelihood of contact
between the TCR and MHC-bound ligand; second, by
increasing the concentration of cytosolic signaling mole-
cules and second messengers at regionally organized focal
points in the proximity of TCRs; and last, by excluding
negative regulatory molecules such as phosphatases from
the zone of antigen receptor signaling (1). The formation
of cap or SMAC requires actin polymerization in T cells
(61). Rac has long been recognized to play a role in recep-
tor-mediated cytoskeletal changes (62). We found that in
the absence of Rac2, T cells showed decreased level of ac-
tin polymerization upon stimulation, accompanied with
reduced antibody cross-linking–induced capping. These
defects are similar to the findings in Vav /  T cells, and
are further evidence of the importance of actin in TCR
signaling.
In summary, our results indicate that Rac2 affects ERK
and p38 activation, Ca2  mobilization, and the cytoskele-
ton reorganization related event, capping, during T cell
activation. These functional defects are similar in nature
but lesser in magnitude compared with the Vav /  T cell
phenotype (21–23). In light of the high homology among
Rac proteins (sharing 89–92% sequence homology), func-
tional overlap among Rho family GTPases (3), and the
compensatory overexpression of Rac1 in Rac2 /  CD4 
T cells, it is conceivable that the moderate phenotypic de-
fect could be due to the compensatory effect of Rac1,
Rac3, and other Rho family GTPases such as CDC42. In
any event, our results corroborate the concept that Rac is
a major substrate of Vav GEF activity, and may relay Vav
signaling during T cell activation. The correlation be-
tween defective T cell activation, defective actin poly-
merization, and defective capping in Rac2 /  T cells
confirms the importance of Rac as a signaling molecule
connecting the TCR signal to cytoskeleton reorganiza-
tion.
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